Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.